We are excited to share a new article from Dagens Industri that highlights why Ziccum’s LaminarPace technology is revolutionary for the pharmaceutical industry, and how groundbreaking findings on increased mRNA activity could mark the beginning of a new era in the mRNA sector.

The article discusses how Ziccum has found a solution to one of the pharmaceutical industry’s biggest challenges: effectively drying complex and fragile mRNA, all while offering significant cost reductions. On top of that, new findings reveal that LaminarPace not only preserves mRNA activity but also enhances it for certain formulations. This means that the pharmaceutical industry potentially could create even more effective treatments and overcome dose limitations.

You may read the full article (in Swedish) here: https://www.di.se/bors/aktier/zicc-4004570/investor-relations/